Search Results
Your search for ,maY matches 17183 pages
Showing 1251 - 1300ACA’s Dependent Coverage Expansion May Have Benefited Young Adult Patients Diagnosed With Cancer
Investigators have uncovered that during the Patient Protection and Affordable Care Act’s (ACA) first decade, the survival rates of Dependent Coverage Expansion–eligible young adult patients with cancer may have improved, according to a recent study published by Roth et al in Cancer. The federal...
Shared Reflections on the 2024 ASCO Annual Meeting: From Networking to Mentorship and More
The ASCO Annual Meeting brings together oncologists, researchers, and health-care professionals to share the latest advancements in cancer care. The 2024 ASCO Annual Meeting (ASCO24) was particularly momentous for those of who received the international development and education award (IDEA). As...
ASHP Offers New Guidance for Managing IV Fluid Shortages
The American Society for Health-System Pharmacists (ASHP) and the University of Utah announced updated recommendations for managing intravenous fluid shortages and conserving supply after Hurricane Helene forced the closure of a critical manufacturing plant in North Carolina. The management and...
PEACE-3: Enzalutamide Plus Radium-223 Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer
Initial analysis from the PEACE-3 trial suggests that the addition of radium-223 dichloride to enzalutamide could offer a promising new first-line treatment option for patients with metastatic castration-resistant prostate cancer, according to data presented by lead study author, Silke Gillessen,...
LEAP-012: Combination of Therapies Extends Progression-Free Survival in Intermediate-Stage Hepatocellular Carcinoma
The combination of the VEGF tyrosine kinase inhibitor lenvatinib, the PD-1 inhibitor pembrolizumab, and transarterial chemoembolization (TACE) significantly improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma (HCC) compared with TACE alone, according to...
AI Language Models May Generate Effective Physician's Letters
An artificial intelligence (AI) algorithm may be effective at writing physician’s letters, according to a recent study published by Heilmeyer et al in JMIR Medical Informatics. Background According to recent surveys, physicians may spend almost 3 hours per day on documentation activities. “The...
ChatGPT May Demonstrate Human-Level Assessment of Brain Tumor MRI Reports
In the field of radiology, where a correct diagnosis is critical to ensure proper patient care, large language models such as ChatGPT may improve accuracy or offer a second opinion in assessing brain tumor magnetic response imaging (MRI) reports, according to a recent study published by Mitsuyama...
NO-CUT Trial: Nonoperative Management of Benefit for Many Patients With Rectal Cancer
Total neoadjuvant therapy (TNT) followed by rectal surgery is the standard of care in proficient mismatch repair (pMMR) locally advanced rectal cancer, but studies are finding that patients with clinical complete response may often avoid surgery and be followed “nonoperatively.” In the first...
Spiritual Themes, Distrust May Factor Into Black Patients’ Reluctance to Participate in Cancer Clinical Trials
Spiritual beliefs and a historically based distrust of clinical research may influence Black patients’ decisions about whether to participate in cancer trials, according to new findings presented by Gomez et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract...
Radiopharmaceutical Therapy May Offer Benefit in Patients With Refractory Meningioma
A radiopharmaceutical therapy has demonstrated early efficacy in patients with difficult-to-treat meningioma, according to new findings presented by Merrell et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 2) and simultaneously published in the...
Certain KRAS Gene Mutations Linked to Improved Prognosis in Pancreatic Cancer
A common mutation in the KRAS gene seems to be associated with improved overall survival in pancreatic ductal adenocarcinoma compared with other variants, in part because the mutation appears to lead to less invasiveness and weaker biological activity, according to a recent study published in...
Strategies for Recovering Neurocognitive Function After Cranial Radiation Therapy
A substantial number of patients with brain metastases who experience cognitive side effects after radiation therapy may fully regain cognitive function, according to recent findings presented by Cherng et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 150). ...
Conversations on Cancer: Exploring Religious Literacy and Spirituality in Cancer Care
OCE Insights is an occasional department developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, the OCE’s Steven Clark Cunningham, MD, MLA, FACS, Clinical Reviewer on the Gastrointestinal Cancers Team, ...
Duration of Postmastectomy Radiation Therapy in Patients Planning Breast Reconstruction
An accelerated course of postmastectomy radiation therapy may not increase complications in patients with breast cancer undergoing breast reconstruction, according to recent findings presented by Poppe et al at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 1) and ...
Navigating Uncharted Waters in the Post-Chevron Sea Change
It is not often that the oncology community looks to the Supreme Court to forecast its future. In 2024, two decisions seemingly unrelated to health care were issued that are likely to have a monumental impact on oncology care delivery. The Court’s rulings—on June 28, Loper Bright Enterprises et ...
ACS Report: Despite Overall Decreases in Breast Cancer Mortality, Incidence Rising in Key Groups
The American Cancer Society (ACS) recently released Breast Cancer Statistics, 2024, the organization’s biennial update on breast cancer occurrence and trends in the United States. The new report finds breast cancer mortality rates overall have dropped by 44% since 1989, averting approximately...
LuPSMA vs Change of Androgen Receptor Pathway Inhibitor in Taxane-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
As reported in The Lancet by Morris et al, the phase III PSMAfore trial has shown improved progression-free survival with lutetium-177–labeled PSMA-617 (LuPSMA) vs change in androgen receptor pathway inhibitor (ARPI) in taxane-naive patients with metastatic castration-resistant prostate cancer...
Standard Chemoradiation May Be Superior to Deintensification Approaches in Patients With HPV-Associated Oropharyngeal Cancer
Deintensified treatment involving a lower radiation dose and immunotherapy in place of chemotherapy may not perform as well as a more rigorous chemoradiation treatment approach in patients with early-stage human papillomavirus (HPV)-associated oropharyngeal cancer, according to new findings...
Intensity-Modulated Radiation Therapy and Proton-Beam Therapy May Offer Equally High Quality of Life and Tumor Control in Patients With Localized Prostate Cancer
Two types of contemporary radiation therapy—proton-beam therapy or intensity-modulated radiation therapy—may provide comparable rates of tumor control with no differences in patient-reported quality of life among patients with low- and intermediate-risk prostate cancer, according to new findings...
Immunotherapy/Chemoradiotherapy for Patients With Limited-Stage Small Cell Lung Cancer
Findings of a multi-institutional phase III trial indicated that people with limited-stage small cell lung cancer may benefit from the addition of immunotherapy to chemoradiotherapy, but not if both treatments are given simultaneously, new research finds. The results suggest that the timing of when ...
KEYNOTE-671: Overall Survival With Perioperative Pembrolizumab in Resectable NSCLC
As reported in The Lancet by Spicer et al, overall survival results of the phase III KEYNOTE-671 trial indicate benefit of the addition of neoadjuvant pembrolizumab to chemotherapy followed by adjuvant pembrolizumab in patients with early-stage non–small cell lung cancer (NSCLC). At the first...
Adding Durvalumab to Neoadjuvant Regimen Improves Pathologic Complete Response Rate in High-Risk Breast Cancer
Adding the immune checkpoint inhibitor durvalumab, with or without the monoclonal antibody oleclumab, to neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) significantly improved pathologic complete response rates in patients with high-risk hormone receptor (HR)-positive breast ...
Cancer and Cancer-Related Therapy May Increase Cardiovascular Disease Risk in Older Cancer Survivors
Investigators have uncovered a higher risk for strokes, heart attacks, and hospital admissions for heart failure in older cancer survivors, according to a recent study published by Muhandiramge et al in Cancer. Background Although advances in cancer treatment have led to decreased mortality rates...
Pharmaceutical Industry Sponsors and Clinical Cancer Research in the United States
Investigators have identified a substantial increase in the proportion of U.S. patients with cancer participating in clinical trials sponsored by the pharmaceutical industry over the past decade compared with those supported by the federal government, according to findings recently presented by...
Creating a Culture of Diversity, Equity, and Inclusion: Why It Matters Clinically and Ethically
The National Comprehensive Cancer Network (NCCN) has always prided itself on its commitment to evidence-based, expert consensus–driven recommendations for cancer care, with a special focus on breaking down the barriers that contribute to disparities in outcomes across all patients with cancer. With ...
Amivantamab-vmjw Plus Lazertinib Improves Long-Term Outcomes in First-Line Setting of EGFR-Mutant Advanced NSCLC
The combination of the EGFR-MET bispecific antibody amivantamab-vmjw and the EGFR tyrosine kinase inhibitor lazertinib continues to demonstrate superior efficacy compared with the kinase inhibitor osimertinib alone in the first-line treatment of EGFR-mutant advanced non–small cell lung cancer...
Updated Findings With Belzutifan in von Hippel-Lindau Disease–Associated CNS Hemangioblastomas
As reported in The Lancet Oncology by Iliopoulos et al, updated findings from the phase II LITESPARK-004 trial support the efficacy of belzutifan in patients with von Hippel-Lindau (VHL) disease–associated CNS hemangioblastomas. Study Details In the study, 50 patients with CNS hemangioblastomas...
Quality Improvements in Lung Cancer Surgery and Tumor Pathology May Extend Survival Postsurgery
Advancing surgical and pathologic techniques may improve overall survival rates in high-risk patients with lung cancer, according to new findings presented by Akinbobola et al at the 2024 ASCO Quality Care Symposium (Abstract 278). Background “Over the past 15 years, a quality improvement...
Conversations Between Physicians and Older Patients About Physical Activity May Reduce Falls During Cancer Treatment
Communication between health-care providers and older patients with cancer regarding the significance of physical activity may help reduce the risk of falls during cancer therapy, according to new findings presented by Lu and Zheng at the 2024 ASCO Quality Care Symposium (Abstract 224). Background...
FDA Approves Selpercatinib for RET Fusion–Positive Medullary Thyroid Cancer
On September 27, 2024, the U.S. Food and Drug Administration granted traditional approval to selpercatinib (Retevmo) for adult and pediatric patients aged 2 years and older with advanced or metastatic medullary thyroid cancer with a RET mutation, as detected by an FDA-approved test, who require...
CABINET Trial Supports Multitargeted Tyrosine Kinase Inhibitor for Advanced Neuroendocrine Tumors
As reported in The New England Journal of Medicine by Chan et al, the multicenter phase III CABINET trial has shown significantly improved progression-free survival with the multitargeted tyrosine kinase inhibitor cabozantinib vs a placebo in previously treated patients with progressive, advanced...
Community-Academic Partnership May Successfully Reduce Radon-Related Lung Cancer Risk in Native Population
A community and academic partnership may provide effective education about the risks of radon, testing for radon, mitigating radon in homes with high levels of the chemical, and reducing the risk of developing lung cancer among Native community members residing in Wisconsin, according to new...
Olanzapine May Reduce Chemotherapy-Induced Nausea and Improve Quality of Life Among Patients With Cancer
Researchers have found that olanzapine may be more effective in controlling severe nausea and improving the quality of life in patients with cancer who are undergoing treatment with chemotherapy, according to new findings presented by Peppone et al at the 2024 ASCO Quality Care Symposium (Abstract...
Quality-of-Life Outcomes: Whole-Breast Irradiation vs Accelerated Partial-Breast Irradiation Following Breast-Conserving Surgery
A study by Ganz et al assessed quality-of-life outcomes following whole- or partial-breast radiation in patients with breast cancer who underwent lumpectomy. The researchers published their findings in the Journal of the National Cancer Institute. Study Methods and Results In the NRG Oncology...
Neighborhood Environment May Be Linked to Prostate Cancer Risk in Men With West African Genetic Ancestry
West African genetic ancestry may be associated with an increased risk of prostate cancer among men residing in disadvantaged neighborhoods but not among those residing in more affluent neighborhoods, according to a recent study published by Pichardo et al in JAMA Network Open. The findings...
More Than Half of AYA Cancer Survivors Experience Financial Toxicity and Are Unable to Afford Food and Housing
A study conducted by Kaitlyn Lapen, MD, a radiation oncologist resident at Memorial Sloan Kettering Cancer Center, and colleagues evaluated the financial challenges adolescent and young adults (AYA) survivors experience during and after treatment. They found that more than half (54%) of these...
Adjuvant Pembrolizumab Following Surgery May Improve Cancer-Free Survival in Patients With High-Risk Urothelial Carcinoma
Treatment with the immunotherapy agent pembrolizumab may nearly double the length that patients with high-risk, muscle-invasive urothelial carcinoma are cancer free following surgical removal of the bladder, according to a recent study published by Apolo et al in The New England Journal of...
Black Patients With Triple-Negative Breast Cancer May Be Less Likely to Receive Immunotherapy Compared With White Patients
Black patients with triple-negative breast cancer may receive immunotherapy at lower rates than White patients, according to new findings presented by Freeman et al at the 2024 American Association for Cancer Research (AACR) Conference on the Science of Cancer Health Disparities in Racial/Ethnic...
Sexual Health Symptoms May Be Linked to Poor Adherence to Adjuvant Endocrine Therapy in Black Women With Breast Cancer
Symptoms related to sexual health may be associated with decreased adherence to adjuvant endocrine therapy among Black women with early-stage breast cancer, according to new findings presented by Anderson et al at the 2024 American Association for Cancer Research (AACR) Conference on the Science of ...
ACA May Increase Access to Colorectal Cancer Care Among Underserved Groups
The Affordable Care Act (ACA) has increased guideline-concordant care for colorectal cancer among non-White patients, those from rural areas, and those from the most deprived neighborhoods in Pennsylvania, according to new findings presented by Kudaravalli et al at the 2024 American Association for ...
Addition of Lu-177–PSMA-617 to Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
In an Australian phase II trial (UpFrontPSMA) reported in The Lancet Oncology, Azad et al found that sequential lutetium (Lu)-177–prostate-specific membrane antigen (PSM)-617 (Lu-177–PSMA-617) and docetaxel was superior to docetaxel alone in achieving undetectable prostate-specific antigen (PSA)...
Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer
On April 29, 2024, tisotumab vedotin-tftv (Tivdak) was granted regular approval for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.1 Tisotumab vedotin is a tissue factor–directed antibody and microtubule inhibitor conjugate. The agent was granted...
Combination Targeted Therapy Produces Durable Remissions in Some Patients With Relapsed Diffuse Large B-Cell Lymphoma
The results from a phase Ib/II study of a five-drug targeted therapy regimen—venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR)—in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) showed the treatment produced durable remissions and potential...
Phase III CABINET Trial: Cabozantinib in Advanced Neuroendocrine Tumors
Cabozantinib may be effective at improving progression-free survival in patients with previously treated neuroendocrine tumors, according to recent findings presented by Chan et al at the European Society for Medical Oncology (ESMO) Congress 2024 (Abstract 1141O) and simultaneously published in The ...
Immunotherapy Combination May Improve Long-Term Survival in Patients With Metastatic Melanoma
Researchers have found that about 50% of patients with metastatic melanoma treated with a combination of nivolumab and ipilimumab experienced cancer-free survival of 10 years or longer, according to a recent study published by Wolchok et al in The New England Journal of Medicine. Background In...
ASCO Issues First Guideline Specific to Locally Advanced Rectal Cancer
ASCO has released its first clinical practice guideline focused specifically on the management of locally advanced rectal cancer.1 “Rectal cancer, and especially locally advanced rectal cancer, is a complex disease that requires individualized approaches using multimodality therapies to have the...
Use of Immune Checkpoint Inhibitors Under Study in High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer
Clinical trials are now demonstrating the value of immune checkpoint inhibitors as neoadjuvant therapy in certain subsets of patients with hormone receptor–positive, HER2-negative breast cancer. Hope S. Rugo, MD, FASCO, described this newer approach—specifically, which subsets of patients may...
Black Women May Have a Higher Risk of Mortality From all Breast Cancer Subtypes
Investigators have found that Black women may have a higher risk of dying from all subtypes of breast cancer compared with White women, according to a recent study published by Torres et al in the Journal of Clinical Oncology. The findings demonstrated that higher mortality rates among Black women...
Breast and Ovarian Cancers May Be Linked to Thousands of RAD51C Gene Variants
Researchers have identified thousands of genetic changes in a gene that may increase the risk of developing breast and ovarian cancers, according to a recent study published by Olvera-León et al in Cell. The findings may pave the way for better risk assessment and more personalized care. ...
Risk of Immune Checkpoint Inhibitor–Induced Diabetes
In a study reported in JAMA Oncology, Ruiz-Esteves et al identified risks for immune checkpoint inhibitor–induced diabetes in patients with cancer. Study Details The retrospective cohort study involved data from 14,328 adult patients with cancer treated with immune checkpoint inhibitors in the Mass ...
